Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. It operates in Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat invasive aspergillosis, and fungal infections; and Boshutai, a small molecule drug to treat diabetes. It is also developing prescription drugs, UOS003(oral PTH) for the treatment of osteoporosis; and rhPTH 1-34 (UNI-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agent for the treatment of Type 2 diabetes and obesity. Uni-Bio Science Group Limited was incorporated in 2001 and is headquartered in Sha Tin, Hong Kong.
Metrics to compare | 0690 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship0690PeersSector | |
---|---|---|---|---|
P/E Ratio | 9.0x | 27.0x | −0.5x | |
PEG Ratio | 0.42 | 0.09 | 0.00 | |
Price/Book | 2.3x | 2.9x | 2.6x | |
Price / LTM Sales | 1.3x | 5.7x | 3.2x | |
Upside (Analyst Target) | - | 10.1% | 42.0% | |
Fair Value Upside | Unlock | 11.1% | 6.6% | Unlock |